Roquefort Therapeutics (ROQ) Competitors GBX 4.12 +0.17 (+4.30%) (As of 11:39 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider Trades ROQ vs. AOR, HEMO, RLM, NSCI, OPTI, ONC, SNG, BVX, CIZ, and APTAShould you be buying Roquefort Therapeutics stock or one of its competitors? The main competitors of Roquefort Therapeutics include AorTech International (AOR), Hemogenyx Pharmaceuticals (HEMO), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), Oncimmune (ONC), Synairgen (SNG), BiVictriX Therapeutics (BVX), Cizzle Biotechnology (CIZ), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry. Roquefort Therapeutics vs. AorTech International Hemogenyx Pharmaceuticals Realm Therapeutics NetScientific OptiBiotix Health Oncimmune Synairgen BiVictriX Therapeutics Cizzle Biotechnology Aptamer Group Roquefort Therapeutics (LON:ROQ) and AorTech International (LON:AOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings. Does the MarketBeat Community favor ROQ or AOR? AorTech International received 77 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRoquefort TherapeuticsN/AN/AAorTech InternationalOutperform Votes7767.54% Underperform Votes3732.46% Which has stronger valuation & earnings, ROQ or AOR? AorTech International has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort Therapeutics£637.008,353.19-£1.54M-£0.01-412.00AorTech International£539K37.09N/A-£3.70-33.38 Does the media prefer ROQ or AOR? In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled AorTech International'saverage media sentiment score. Company Overall Sentiment Roquefort Therapeutics Neutral AorTech International Neutral Do institutionals & insiders have more ownership in ROQ or AOR? 1.7% of Roquefort Therapeutics shares are held by institutional investors. 60.4% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ROQ or AOR more profitable? AorTech International's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort TherapeuticsN/A -27.05% -15.86% AorTech International N/A N/A N/A SummaryAorTech International beats Roquefort Therapeutics on 5 of the 9 factors compared between the two stocks. Ad StockEarnings“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to pop now that Donald Trump has been re-electedClaim your copy before they move Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ROQ and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROQ vs. The Competition Export to ExcelMetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£5.32M£166.09M£5.14B£1.41BDividend YieldN/A3.50%5.02%11.75%P/E Ratio-412.00325.76132.411,551.66Price / Sales8,353.1915,590.941,239.48207,748.86Price / Cash1.4911.7939.4532.98Price / Book1.037.096.972.83Net Income-£1.54M-£18.37M£118.75M£152.66M7 Day Performance3.78%0.53%1.70%8.24%1 Month Performance9.57%7.51%-3.42%3.79%1 Year Performance-36.62%28.52%32.40%91.90% Roquefort Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROQRoquefort TherapeuticsN/AGBX 4.12+4.3%N/A-41.3%£5.32M£637.00-412.009Gap UpHigh Trading VolumeAORAorTech InternationalN/AGBX 123.50-2.4%N/A+0.0%£19.99M£539,000.00-33.383HEMOHemogenyx PharmaceuticalsN/AGBX 1.20-21.3%N/A-38.3%£16.08MN/A-109.0014News CoverageGap UpHigh Trading VolumeRLMRealm TherapeuticsN/AGBX 11.50flatN/A+0.0%£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 12.40+1.2%N/A-55.5%£12.15M£1.26M-387.401Gap DownHigh Trading VolumeONCOncimmuneN/AGBX 15.90+5.0%N/A-32.4%£11.79M£1.21M-504.6752Positive NewsSNGSynairgenN/AGBX 4.49-3.1%N/A-23.1%£9.03M£79,000.00-163.0334Gap UpBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/A-9.1%£8.25MN/A-250.0017Gap UpHigh Trading VolumeCIZCizzle BiotechnologyN/AGBX 1.94+2.1%N/A-9.5%£7.69M£25,000.00-183.004Gap UpAPTAAptamer GroupN/AGBX 0.35+18.3%N/A-82.6%£6.70M£1.03M-4.2537Gap UpHigh Trading Volume Related Companies and Tools Related Companies AOR Alternatives HEMO Alternatives RLM Alternatives NSCI Alternatives OPTI Alternatives ONC Alternatives SNG Alternatives BVX Alternatives CIZ Alternatives APTA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:ROQ) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
